DudeMeds Review
Best for: men seeking no-fee GLP-1 access with oral and injectable options
DudeMeds is a men's telehealth platform offering semaglutide and tirzepatide in both oral and injectable formats from $149/month. No membership fee, no doctor fee, free shipping. Also offers TRT, ED, and hair loss treatments. Accepts clinic-switch patients from existing GLP-1 and TRT providers.
Medium confidence · Last verified 2026-04-10 via Chrome MCP live pull · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
DudeMeds is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
DudeMeds prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| GLP-1 starting price | compounded | $149 |
✓ Pros
- •Both semaglutide and tirzepatide available in oral and injectable formats
- •No membership fee, no doctor fee, free shipping — transparent all-in pricing from $149/mo
- •HSA and FSA eligible
- •Accepts clinic-switch patients from existing GLP-1 and TRT providers
- •Async consultations in most states — no video visit required
- •24/7 patient portal for ongoing care and medication adjustments
- •Fast delivery — medication typically ships within 48 hours
✗ Cons
- •Men's-only branding — may not appeal to women seeking GLP-1 access
- •State availability not publicly disclosed — described as available in 'most states'
- •No visible LegitScript certification or PCAB accreditation
- •Newer brand with limited independent reviews
- •Exact dose-tier pricing beyond the $149 starting price is not disclosed on the website
Ready to start with DudeMeds?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our DudeMeds review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to DudeMeds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with DudeMeds?
Starting at $149/month. See current pricing and start your free consultation.